Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $80.23 Consensus PT from Brokerages

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been assigned an average rating of “Moderate Buy” from the fourteen analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $80.2308.

A number of research firms have recently commented on RARE. Barclays reduced their target price on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a research report on Monday, November 24th. TD Cowen cut their price objective on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Truist Financial lowered their target price on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 9th.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 3,081 shares of the stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $36.38, for a total transaction of $112,086.78. Following the transaction, the chief financial officer directly owned 95,146 shares in the company, valued at $3,461,411.48. This represents a 3.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 5.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently modified their holdings of RARE. Covestor Ltd increased its holdings in Ultragenyx Pharmaceutical by 26.0% in the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 369 shares during the last quarter. Huntington National Bank lifted its holdings in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 393 shares during the last quarter. Teacher Retirement System of Texas grew its position in shares of Ultragenyx Pharmaceutical by 1.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock worth $828,000 after acquiring an additional 404 shares in the last quarter. Xponance Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 3.1% in the 3rd quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock valued at $406,000 after acquiring an additional 406 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Ultragenyx Pharmaceutical by 2.3% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,988 shares of the biopharmaceutical company’s stock valued at $690,000 after acquiring an additional 434 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Down 1.1%

Shares of NASDAQ RARE opened at $34.19 on Thursday. The stock has a fifty day moving average price of $33.95 and a 200 day moving average price of $32.28. Ultragenyx Pharmaceutical has a 12-month low of $25.81 and a 12-month high of $46.50. The company has a market cap of $3.30 billion, a P/E ratio of -5.76 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.58). The company had revenue of $159.93 million during the quarter, compared to analysts’ expectations of $167.42 million. Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.Ultragenyx Pharmaceutical’s quarterly revenue was up 14.6% on a year-over-year basis. During the same period in the previous year, the company earned ($1.40) EPS. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.